Please login to the form below

Not currently logged in
Email:
Password:

Kantar’s Gracie van Kemenade appointed quantitative director at Insight Research Group

Paul O’Meara also joins as regional head of syndicated studies

Gracie van Kemenade has left Kantar Health to join Insight Research Group as quantative director.

She is joined at the market research company by fellow new recruit Paul O'Meara, who has been appointed regional head of syndicated studies.

Van Kemenade was previously global account lead for major pharmaceutical companies at Kantar, and will work across the whole research team in her new role at Insight.

Her main focus will be to work with Insight's existing quantitative research team and apply her experience in the development of new proprietary quantitative research methodologies.

In addition, van Kemenade has experience in market landscape, target product profiling, patient record studies, launch tracking and brand equity research.

Grace van Kemenade - Insight Research GroupPaul O'Meara - Insight Research Group
Gracie van Kemenade and Paul O'Meara

O'Meara was most recently at Ipsos Healthcare where he was head of syndicated studies for the Asia-Pacific region.

Nicola Cowland, joint CEO at Insight Research Group, said of O'Meara and van Kemenade: “Their recruitment is the latest step in bolstering Insight's quantitative research capabilities, developing innovative and valuable new research offerings and affirming our presence as a leading global player in quantitative, qualitative and digital market research in the healthcare sector.”

21st August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics